HOME
 Acute Myelogenous
 Leukemia (AML)
 Other Leukemia Types
 (ALL / CLL / CML / HCL)
 Myelodysplastic Syndrome
 Symptoms and Diagnosis
 Leukemia Treatment Options
  " Chemotherapy
  " Blood Stem Cell Transplants
  " Radiation and Surgery
  " Chemo Side Effects
  " Clinical Trials Info
  " Coping with Leukemia
  " What to Ask Your Doctor
 Financial Assistance
 At Risk Jobs/Exposure
 Leukemia Resources
 Survivor's Story
 Leukemia News

 Search for information:
 
      Match:
any search words
all search words

Click Here for a Free
Information Packet

FOR MORE INFORMATION
Please call
1-800-913-6370

We will gladly answer your
questions and send a free
packet with additional
information on:

  • New treatment options
  • New clinical trials
  • Doctors
  • Hazardous jobs and products
  • Medical Financial Aid

 





 
Acute myelogenous leukemia picture

 Blood Cancer &
 Leukemia

Medical information about cancer

  Leukemia Cancer Information

Leukemia symptoms

Leukemia Cancer News - Return to Menu

Former LFO Lead Singer Battles Leukemia

By: ChartAttack.com Staff

Wednesday April 20, 2005 - Rich Cronin, lead singer of former teen heartthrobs LFO has been hospitalized with leukemia.

Cronin was diagnosed on March 28 with acute myelogenous leukemia. He is currently receiving treatment at the Beth Israel Deaconess Medical Centre near Boston, his hometown.

MTV.com reports Cronin went through his first session of chemotherapy last week, but is still unsure if the cancer will go into remission.

The former pop sensation has been relatively quiet since the demise of his band LFO, and was working on his inaugural solo project. In late February, Cronin reportedly started to feel chronically tired and started getting pretty sharp headaches. Initially, the pop singer dismissed the symptoms, but consulted a doctor when they persisted. Upon finishing his recording in New York, he went back home to Boston, where he ultimately discovered the bad news.

Since being diagnosed, a number of other pop stars, including Jeff Timmons of 98 Degrees, Jordan Knight formerly of New Kids On The Block and Cronins former bandmates Devin Lima and Brad Fischetti, have publicly offered support.

With all of your love, support and prayers, he will pull through this, Lima said in a posting on his website.

Since being stricken with the illness, Cronin said his entire outlook on life has changed. Proceeds of his upcoming release will go towards the Leukemia & Lymphoma Society.

Justin Krever


REVLIMID(R) New Drug Application Submitted to FDA for Review

Clinical Data From Phase II Trial (MDS-003) in Patients With Myelodysplastic Syndromes With 5q Deletion Chromosomal Abnormality Submitted

SUMMIT, N.J., April 8 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that it has completed the rolling submission of its New Drug Application (NDA) for REVLIMID (lenalidomide), an investigational drug, to the Division of Oncology Drug Products at the U.S. Food and Drug Administration (FDA) for review. The Company's NDA is seeking approval to market REVLIMID as a treatment for transfusion-dependent patients with myelodysplastic syndromes (MDS) with a 5q deletion chromosomal abnormality.

MDS is a malignant disorder of blood cell production that affects approximately 300,000 people worldwide. The most common clinical manifestation associated with MDS is refractory anemia, and the multiple complications that stem from frequent blood transfusions. Celgene's lead IMiD(R) (Immunomodulatory drug), REVLIMID has received both orphan drug status and fast track designation from the U.S. Food and Drug Administration (FDA) and orphan drug status from the European Agency for the Evaluation of Medicinal Products for the treatment of MDS.

"Celgene appreciates and acknowledges the efforts of all those who made this filing possible, including: the more than 400 patients who participated in these MDS studies, and the international community of clinical investigators who have helped us get to this stage in the regulatory process." said Jerome B. Zeldis, M.D., Ph.D., Chief Medical Officer and VP, Medical Affairs of Celgene Corporation.

About REVLIMID(R)

REVLIMID is a member of a new class of novel immunomodulatory drugs, or IMiDs(R). Celgene is evaluating treatments with REVLIMID for a broad range of hematology and oncology conditions, including; multiple myeloma, the malignant blood cell disorders known as myelodysplastic syndromes (MDS) as well as solid tumor cancers. REVLIMID affects multiple intracellular biological pathways. The IMiD pipeline, including REVLIMID, is covered by a comprehensive intellectual property estate of U.S. and foreign issued and pending patent applications including composition-of-matter and use patents.

REVLIMID(R) (lenalidomide) is not approved by the FDA or any other regulatory agencies as a treatment in any indication and is currently being evaluated in clinical trials for efficacy and safety for future regulatory applications.

About Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) are a group of hematologic malignancies that affect approximately 300,000 people worldwide. Myelodysplastic syndromes occur when blood cells remain in an immature or "blast" stage within the bone marrow and never develop into mature cells capable of performing their necessary functions. Eventually, the bone marrow may be filled with blast cells suppressing normal cell development. According to the American Cancer Society, 10,000 to 20,000 new cases of MDS are diagnosed each year in the United States, with mean survival rates ranging from approximately six months to six years for the different classifications of MDS. MDS patients must often rely on blood transfusions to manage symptoms of anemia and fatigue until they develop life-threatening iron overload and/or toxicity, thus underscoring the critical need for new therapies targeting the cause of the condition rather than simply managing its symptoms.

About 5q Deletion Chromosomal Abnormality

Chromosomal (cytogenetic) abnormalities are detected in more than half of patients with myelodysplastic syndrome (MDS), and involve a deletion in all or part of one or more specific chromosomes. The most common cytogenetic abnormalities in MDS are deletions in the long arm of chromosomes 5, 7, and 20. Another common abnormality is an extra copy of chromosome 8. A deletion involving the 5q chromosome may be involved in 20 to 30% of all MDS patients. The World Health Organization has also recently identified a unique subset of MDS patients with a "5q- Syndrome" where the only chromosomal abnormality is a specific portion of the 5q chromosome.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global pharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit the Company's website at http://www.celgene.com .

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control, which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending research and development activities, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission such as 10K, 10Q and 8K reports.

CONTACT:
Robert J. Hugin
Senior VP and CFO
+1-908-673-9102

Brian P. Gill
Director PR-IR
Celgene Corporation
+1-908-673-9530


 


 


To Obtain the Best Treatment Info & Financial Assistance contact us for a FREE INFORMATION PACKET which includes:

Cancer Hospital Locations
Clinical Trials
Hazardous Jobs/ Products
New Treatment Options
Doctors
Financial Assistance

Fill out the form below or call 1-800-913-6370.

First Name
Last Name
Address
City
State
Zip

Phone

Email
   
Have you or a loved one been diagnosed or have:
   
Acute Myelogenous
Leukemia (AML)?
Yes  No
Myelodysplastic Syndrome (MDS)?

Yes  No
Aplastic Anemia?

Yes  No
Non-Hodgkin Lymphoma (NHL)?
Yes  No
Any other Leukemia
or Blood Disease?
( In the comment section below please state the diagnosis)

Yes  No
Did you or your loved one ever work around benzene?
Display At Risk Jobs / Exposure
Yes  No

How old is the patient?

 
   

Comment/
Info Request 

 

 

Site Map | Acute Myelogenous Leukemia